Additional file 1: of A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

IRB/Human subjects protection offices list for PROCLAIM Registry. (DOCX 10 kb

Additional file 1: of An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

Cancer Immunotherapy Guidelines- Cutaneous melanoma version 2.0 Task Force Roster. (DOCX 13 kb

Additional file 3: of An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

Cancer Immunotherapy Guidelines (Melanoma). (DOCX 145 kb

Legislative Documents

Also, variously referred to as: House bills; House documents; House legislative documents; legislative documents; General Court documents

Additional file 2: of Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Figure S1. Study schema. (TIF 18129 kb

Additional file 5: of Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Figure S4. Genomic mutational landscape of melanoma cohort. (TIFF 16875 kb

Additional file 4: of Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Figure S3. Gene expression and survival. (TIFF 33984 kb

Additional file 6: of Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Figure S5. Linear model AUC for “leave one out” validation of training set. (TIFF 16875 kb

Additional file 7: of Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Supplementary appendix including additional methods and results. (DOCX 40 kb